For labs, the big takeaway is how prominently molecular testing and profiling figures in so many aspects of the NCCN’s recommendations.
Subscribe today for full access
to all of these articles.
The VALID Act for FDA regulation of laboratory developed tests is working its way through the final stages of the legislative process, but not everyone is loving it.
The market is expected to grow at a CAGR of 3.21 percent from 2021 to 2028 and reach $17.432 billion by 2028, according to a recent report.
Danielle H. Tangorre discusses key takeaways for labs from the DOJ’s recent nationwide takedown of $1.2 billion in alleged schemes.
As the outbreak continues to grow in countries that have not historically seen monkeypox cases, testing companies are stepping up.
Here are the aspects of the proposed rule most likely to have an impact on labs and the businesses that own them.